Analysts’ Weekly Ratings Changes for Alder Biopharmaceuticals (ALDR)

Share on StockTwits

A number of research firms have changed their ratings and price targets for Alder Biopharmaceuticals (NASDAQ: ALDR):

  • 2/18/2019 – Alder Biopharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 2/12/2019 – Alder Biopharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 2/11/2019 – Alder Biopharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 2/6/2019 – Alder Biopharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 2/1/2019 – Alder Biopharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 1/30/2019 – Alder Biopharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 1/17/2019 – Alder Biopharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/14/2019 – Alder Biopharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 1/11/2019 – Alder Biopharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. “
  • 1/5/2019 – Alder Biopharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

Shares of Alder Biopharmaceuticals stock opened at $14.04 on Thursday. The company has a debt-to-equity ratio of 0.97, a current ratio of 15.34 and a quick ratio of 15.34. The stock has a market capitalization of $959.35 million, a P/E ratio of -2.84 and a beta of 2.87. Alder Biopharmaceuticals Inc has a 1 year low of $9.44 and a 1 year high of $20.87.

In related news, insider Jeffrey T. L. Smith sold 5,044 shares of the stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $13.84, for a total value of $69,808.96. Following the completion of the transaction, the insider now directly owns 5,875 shares in the company, valued at approximately $81,310. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 17.40% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Cornerstone Wealth Management LLC bought a new position in shares of Alder Biopharmaceuticals in the 3rd quarter worth about $400,000. Pacer Advisors Inc. bought a new position in shares of Alder Biopharmaceuticals in the 3rd quarter worth about $118,000. Brighton Jones LLC bought a new position in shares of Alder Biopharmaceuticals in the 3rd quarter worth about $197,000. Stifel Financial Corp bought a new position in shares of Alder Biopharmaceuticals in the 4th quarter worth about $154,000. Finally, Hsbc Holdings PLC bought a new position in shares of Alder Biopharmaceuticals in the 4th quarter worth about $176,000.

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Further Reading: What is the price-sales ratio?

Receive News & Ratings for Alder Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stock Analysts’ Downgrades for March, 19th
Stock Analysts’ Downgrades for March, 19th
Aceto  Stock Price Down 5.3%
Aceto Stock Price Down 5.3%
Pandacoin Price Tops $0.0001 on Major Exchanges
Pandacoin Price Tops $0.0001 on Major Exchanges
Gainer Reaches 24-Hour Trading Volume of $0.00
Gainer Reaches 24-Hour Trading Volume of $0.00
PoSW Coin 24 Hour Trading Volume Hits $3.00
PoSW Coin 24 Hour Trading Volume Hits $3.00
BitDice  24-Hour Volume Hits $7.00
BitDice 24-Hour Volume Hits $7.00


© 2006-2019 Ticker Report